An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2018
Price : $35 *
At a glance
- Drugs PT 2385 (Primary)
- Indications Renal cell carcinoma; Von Hippel-Lindau disease
- Focus Therapeutic Use
- Sponsors Peloton Therapeutics
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 11 May 2017 According to a Peloton Therapeutics media release, patient dosing has been initiated in this trial.